Oral Biologics & Biosimilar Drugs Global Market Report 2024

Description

A biosimilar is a medication designed to closely resemble a biologic drug both structurally and functionally. Biologic drugs are treatments produced using biological systems like yeast, bacteria, or animal cells. A biological product is deemed 'biosimilar' if it closely matches an FDA-approved reference product with no clinically discernible differences.

Within therapy types, there are oral biologics and biosimilars categorized as lymphocyte modulators, interleukin inhibitors, and tumor necrosis factor-alpha inhibitors. Interleukin inhibitors are immunosuppressive drugs that hinder interleukins' functionality. Interleukins are a group of cytokines generated by lymphocytes, monocytes, macrophages, and various other cells, crucial in regulating the immune system. These drugs treat various conditions such as asthma, Crohn's disease, carcinoma, arthritis, diabetes, multiple myeloma, enterocolitis, multiple sclerosis, sarcoma, psoriasis, and others. They are available in forms like vaccines, proteins, peptides, monoclonal antibodies, distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The oral biologics and biosimilar market research report is one of a series of new reports from The Business Research Company that provides oral biologics and biosimilar market statistics, including oral biologics and biosimilar industry global market size, regional shares, competitors with an oral biologics and biosimilar market share, detailed oral biologics and biosimilar market segments, market trends and opportunities, and any further data you may need to thrive in the oral biologics and biosimilar industry. This oral biologics and biosimilar market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The oral biologics & biosimilar drugs market size has grown exponentially in recent years. It will grow from $5.94 billion in 2023 to $7.19 billion in 2024 at a compound annual growth rate (CAGR) of 21.0%. The growth observed in the historical period can be attributed to several factors, including an increased prevalence of chronic diseases, heightened awareness surrounding oral biologics, the expiration of patents on existing medications, and an escalating demand for biosimilars.

The oral biologics & biosimilar drugs market size is expected to see exponentially grown in the next few years. It will grow to $13.32 billion in 2028 at a compound annual growth rate (CAGR) of 16.7%. Anticipated growth in the forecast period is driven by several factors, notably the expansion of targeted therapy, a growing emphasis on preventive medicine, increased healthcare expenditures, and an aging population. Major trends expected during this period encompass advancements in oral delivery technology, the development of orally administered biologics, innovative strides in biosimilars, and a shift towards patient-centric care models.

The prevalence of chronic conditions like arthritis, asthma, and cancer is anticipated to drive growth in the oral biologics and biosimilar market. Factors such as extended work hours, limited physical activity, and unhealthy dietary habits contribute to the rise in chronic diseases, and biologics are increasingly utilized for their treatment. These medications trigger the immune system to combat cancer cells, aiding in their elimination. The United Nations projects that by 2030, about 70% of global deaths will be attributed to chronic diseases, with the global burden of these conditions expected to reach approximately 60%. Consequently, the surge in chronic diseases is expected to fuel demand for biologics and biosimilars, spurring growth in the oral biologics and biosimilar drugs market.

The escalating demand for personalized medicine is set to propel growth in the oral biologics and biosimilar drugs market. Personalized medicine involves tailoring medical decisions and drug therapies to individual patients. This approach aligns with the development and utilization of oral biologics and biosimilars, optimizing treatment efficacy while minimizing side effects and reducing trial-and-error methods, leading to higher response rates and extended survival. Reports by STAT in October 2022 indicated over 75,000 genetic testing products and 300 personalized medicines, underscoring the increasing demand for personalized medicine driving growth in the oncology molecular diagnostics market.

A noteworthy trend in the oral biologics and biosimilar market is the creation of new insulin biosimilars. Key market players are investing in developing biosimilar versions of insulin, fostering competition among different biosimilar manufacturers. For instance, in April 2023, Eli Lilly and Company introduced Rezvoglar (insulin glargine-aglr), a biosimilar of insulin glargine used for improving glycemic control in adults, children, and infants with type 1 diabetes, as well as adults with type 2 diabetes.

Major players in the oral biologics and biosimilar market are concentrating on innovative products like interchangeable biosimilars to drive market revenues. Interchangeable biosimilars meet specific regulatory requirements, allowing them to be substituted for the reference biologic product without the intervention of the prescribing healthcare provider. For example, in November 2021, Viatris Inc. and Biocon Biologics Limited launched SEMGLEE (insulin glargine-yfgn) injection and Insulin Glargine (insulin glargine-yfgn) injection. These interchangeable biosimilars aid adults with type 2 diabetes and children with type 1 diabetes in managing high blood sugar, substituting for the reference brand LANTUS (insulin glargine) and available in vial and prefilled pen formats for pharmacy counter substitution.

Major companies operating in the oral biologics & biosimilar drugs market include Novartis International AG, Rani Therapeutics Holdings Inc., Eli Lilly and Company, AstraZeneca PLC, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals Inc., BiosanaPharma, Entera Bio Ltd., Allergan PLC, Emisphere Technologies Inc., Enteris BioPharma Inc., Chiasma Inc., Allena Pharmaceuticals Inc., Gelgen Corporation, Ganlee Corporation, 3SBio Inc., Innovent Biologics Inc., Retractable Technologies Inc., Changchun High & New Technology Industries (Group) Inc., Dong Bao Pharmaceutical Co. Ltd., CP Guojian Pharmaceutical Co. Ltd., GlaxoSmithKline PLC, Concord Biotech Limited, Aurobindo Pharma Limited, H. Lundbeck A/S, Sanofi S.A., F. Hoffmann-La Roche Ltd., Allergan Pharmaceuticals International Limited, Hikma Pharmaceuticals PLC, Mylan N.V., Pfizer Inc., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd.

North America was the largest region in the oral biologics and biosimilar drugs market in 2023. The Middle East is expected to be the fastest growing region in the oral biologics & biosimilar drugs market report during the forecast period. The regions covered in the oral biologics & biosimilar drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the oral biologics & biosimilar drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The oral biologics and biosimilar market consist of sales of therapeutic proteins, cystic fibrosis, somatic cells, and allergenics. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oral Biologics & Biosimilar Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oral biologics & biosimilar drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oral biologics & biosimilar drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oral biologics & biosimilar drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Therapy: Lymphocyte Modulators; Interleukin Inhibitors; Tumor Necrosis Factor-Alpha Inhibitors
2) By Disease: Asthma; Crohn's Disease; Carcinoma; Arthritis; Diabetes; Multiple Myeloma; Enterocolitis; Multiple Sclerosis; Sarcoma; Psoriasis and Others
3) By Molecule Type: Vaccines; Proteins & Peptides; Monoclonal Antibodies; Other Molecule Types
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies Mentioned: Novartis International AG; Rani Therapeutics Holdings Inc.; Eli Lilly and Company; AstraZeneca plc; Novo Nordisk A/S
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r13252

1. Executive Summary

2. Oral Biologics & Biosimilar Drugs Market Characteristics

3. Oral Biologics & Biosimilar Drugs Market Trends And Strategies

4. Oral Biologics & Biosimilar Drugs Market - Macro Economic Scenario

4.1. Impact Of High Inflation On the Market
4.2. Ukraine-Russia War Impact On the Market
4.3. COVID-19 Impact On the Market

5. Global Oral Biologics & Biosimilar Drugs Market Size and Growth

5.1. Global Oral Biologics & Biosimilar Drugs Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Oral Biologics & Biosimilar Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Oral Biologics & Biosimilar Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Oral Biologics & Biosimilar Drugs Market Segmentation

6.1. Global Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Lymphocyte Modulators
Interleukin Inhibitors
Tumor Necrosis Factor-Alpha Inhibitors
6.2. Global Oral Biologics & Biosimilar Drugs Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Asthma
Crohn's Disease
Carcinoma
Arthritis
Diabetes
Multiple Myeloma
Enterocolitis
Multiple Sclerosis
Sarcoma
Psoriasis and Others
6.3. Global Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Vaccines
Proteins & Peptides
Monoclonal Antibodies
Other Molecule Types
6.4. Global Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

7. Oral Biologics & Biosimilar Drugs Market Regional And Country Analysis

7.1. Global Oral Biologics & Biosimilar Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Oral Biologics & Biosimilar Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Oral Biologics & Biosimilar Drugs Market

8.1. Asia-Pacific Oral Biologics & Biosimilar Drugs Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Oral Biologics & Biosimilar Drugs Market

9.1. China Oral Biologics & Biosimilar Drugs Market Overview
9.2. China Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Oral Biologics & Biosimilar Drugs Market

10.1. India Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Oral Biologics & Biosimilar Drugs Market

11.1. Japan Oral Biologics & Biosimilar Drugs Market Overview
11.2. Japan Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Oral Biologics & Biosimilar Drugs Market

12.1. Australia Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Oral Biologics & Biosimilar Drugs Market

13.1. Indonesia Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Oral Biologics & Biosimilar Drugs Market

14.1. South Korea Oral Biologics & Biosimilar Drugs Market Overview
14.2. South Korea Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Oral Biologics & Biosimilar Drugs Market

15.1. Western Europe Oral Biologics & Biosimilar Drugs Market Overview
15.2. Western Europe Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Oral Biologics & Biosimilar Drugs Market

16.1. UK Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Oral Biologics & Biosimilar Drugs Market

17.1. Germany Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Oral Biologics & Biosimilar Drugs Market

18.1. France Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Oral Biologics & Biosimilar Drugs Market

19.1. Italy Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Oral Biologics & Biosimilar Drugs Market

20.1. Spain Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Oral Biologics & Biosimilar Drugs Market

21.1. Eastern Europe Oral Biologics & Biosimilar Drugs Market Overview
21.2. Eastern Europe Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Oral Biologics & Biosimilar Drugs Market

22.1. Russia Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Oral Biologics & Biosimilar Drugs Market

23.1. North America Oral Biologics & Biosimilar Drugs Market Overview
23.2. North America Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Oral Biologics & Biosimilar Drugs Market

24.1. USA Oral Biologics & Biosimilar Drugs Market Overview
24.2. USA Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Oral Biologics & Biosimilar Drugs Market

25.1. Canada Oral Biologics & Biosimilar Drugs Market Overview
25.2. Canada Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Oral Biologics & Biosimilar Drugs Market

26.1. South America Oral Biologics & Biosimilar Drugs Market Overview
26.2. South America Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Oral Biologics & Biosimilar Drugs Market

27.1. Brazil Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Oral Biologics & Biosimilar Drugs Market

28.1. Middle East Oral Biologics & Biosimilar Drugs Market Overview
28.2. Middle East Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Oral Biologics & Biosimilar Drugs Market

29.1. Africa Oral Biologics & Biosimilar Drugs Market Overview
29.2. Africa Oral Biologics & Biosimilar Drugs Market, Segmentation By Therapy, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Oral Biologics & Biosimilar Drugs Market, Segmentation By Molecule Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Oral Biologics & Biosimilar Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Oral Biologics & Biosimilar Drugs Market Competitive Landscape And Company Profiles

30.1. Oral Biologics & Biosimilar Drugs Market Competitive Landscape
30.2. Oral Biologics & Biosimilar Drugs Market Company Profiles
- 30.2.1. Novartis International AG
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Rani Therapeutics Holdings Inc.
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Eli Lilly and Company
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. AstraZeneca plc
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Novo Nordisk A/S
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Global Oral Biologics & Biosimilar Drugs Market Competitive Benchmarking

32. Global Oral Biologics & Biosimilar Drugs Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Oral Biologics & Biosimilar Drugs Market

34. Oral Biologics & Biosimilar Drugs Market Future Outlook and Potential Analysis

34.1 Oral Biologics & Biosimilar Drugs Market In 2028 - Countries Offering Most New Opportunities
34.2 Oral Biologics & Biosimilar Drugs Market In 2028 - Segments Offering Most New Opportunities
34.3 Oral Biologics & Biosimilar Drugs Market In 2028 - Growth Strategies
- 34.3.1 Market Trend Based Strategies
- 34.3.2 Competitor Strategies

35. Appendix

35.1. Abbreviations
35.2. Currencies
35.3. Historic And Forecast Inflation Rates
35.4. Research Inquiries
35.5. The Business Research Company
35.6. Copyright And Disclaimer